The World Health Organization (WHO) classification (2008) is widely used to diagnose polycythemia vera (PV).
Introduction
Myeloproliferative neoplasm (MPN) is a neoplastic disease characterized by an abnormal increase in hematopoietic cells. Philadelphia chromosome (Ph) -negative MPN, excluding chronic myeloid leukemia, mainly includes polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). Previous studies reported that the JAK2V617F gene mutation was frequently detected in Ph-negative MPN cases in 2005 (> 95% in PV and 50-60% in ET and PMF) 1)-5) . The prognosis of patients with PV is greatly influenced by thrombosis and leukemic transformation 6) . Therefore, PV should be managed in a manner that depends on an early accurate diagnosis before the development of complications.
PV is currently diagnosed using the WHO classification (2008) 7) which specifically employs two main criteria: (1) evidence of either an increase in hemoglobin (Hb) levels (male: > 18.5 g/dl; female: > 16.5 g/dl) or the RBC count and (2) the presence of either JAK2V617F or exon 12 mutations, and three minor criteria: (1) findings of three types of hyperplasia in bone marrow biopsy samples, (2) low serum erythropoietin (EPO) levels, and (3) the formation of endogenous erythroid colonies (EEC). Of these, two main criteria and one minor criterion, or first one of the two main criteria and two minor criteria should be met for a definite PV diagnosis. Hb levels have been employed in the WHO classification as the main criterion reflecting red cell . Since the JAK2 gene mutation is frequently detected in PV, the BCSH guidelines recommended that PV can be diagnosed based on Ht levels (> 52% in males and > 48% in females) if the presence of JAK2V617F or exon 12 gene mutations can be demonstrated, and also that JAK2 gene mutation-negative cases can be diagnosed as PV based on exclusion items, such as the absence of splenomegaly and secondary polycythemia. Furthermore, a bone marrow examination is not necessarily required by the BCSH criteria.
The JAK2 gene mutation is included in both the WHO and BCSH criteria for PV, and has become essential in the diagnosis of PV. We previously developed a JAK2V617F allele burden quantification method (ABC-PCR method) using peripheral blood 14) . In the present study, we utilized this JAK2 mutation detection method and examined the usefulness of the BCSH criteria for diagnosing PV in Japanese patients.
Patients and Methods

Study population
A total of 194 patients from 20 facilities, for whom consent was obtained after approval (No. 21,076) by the Juntendo University Ethics Committee between April 2010 and December 2013, were included. Peripheral blood was collected from patients to be used in the JAK2 gene analysis. The following clinical data entered by the attending physicians were collected: date of the first visit, blood counts at the time of the diagnosis or sample submission for a genetic analysis (WBC, differential WBC, RBC, and platelet counts, Hb, Ht, serum EPO, bone marrow biopsy, splenomegaly [palpation and imaging (ultrasonography or computed tomography (CT) ) ], and a history of thrombosis or prior treatment until blood sample submission. Blood count data collected at the first visit or diagnosis were used. Bone marrow biopsies were histologically diagnosed in reference to pathologistsʼ findings at each facility.
JAK2V617F mutation analysis
Five milliliters of peripheral blood was collected from the patients, followed by DNA extraction from the whole blood. The JAK2V617F allele burden was quantified using the ABC-PCR method 14) . An allele burden of > 10% was regarded as positive (sensitivity: 5-10%). Patients with cut-off values of approximately 10% were re-examined using the AS-qPCR method.
JAK2 exon 12 mutation analysis
DNA was extracted from the EEC of JAK2V617F-negative cases clinically suspected of having PV, followed by an analysis for the exon 12 mutation 15) .
Statistical analysis
All statistical analyses were performed by JMP ® 10 (SAS Institute Inc., Cary, NC, USA). The level of significance was two-sided p < 0.05. A t-test or Fisherʼ s exact test was used to compare the two groups, depending on the type of data. After grouping depending on the presence or absence of a history of thrombosis, the odds ratio of thrombosis was estimated using a logistic model including age, sex, JAK2V617F allele burden, blood counts, EPO, splenomegaly, and cardiovascular risk factors (smoking, hypertension, dyslipidemia, and diabetes) as explanatory variables. The final model was selected using the minimum AICc criterion (AICc is the finite corrected Akaikeʼ s information criterion) 16) .
Results
PV patient profiles
As shown in Table- 1, 99 patients were diagnosed with PV based on the criteria of the BCSH guidelines (Group A) while 69 patients were diagnosed according to the WHO criteria (Group B). All patients in Group B fit the PV BCSH criteria. Although bone marrow biopsy is required for the detection of hyperplasia 17) which is included in the WHO minor criteria, it could not conducted in some patients who had been administered an anti-platelet agent or were of an advanced age. In the present study, bone marrow biopsy was not conducted in 20 out of 30 cases that met the PV criteria of the BCSH criteria, but did not fulfill the WHO criteria. This was one of the major reasons why patients having both of the major criteria did not meet the WHO criteria. Another main reason was the lack of serum EPO data (Table-2 ). Figure-1 shows the schema of Group A (BCSH (+)), Group B (BCSH (+) /WHO (+)), and Group C ((BCSH (+)/WHO (−)). The profiles of patients diagnosed by BCSH (Group A, n = 99) and WHO (Group B, n = 69) were compared (Table-1). As described above, all patients in Group B met the diagnostic criteria of the BCSH criteria, indicating that Group A contained all the patients of Group B. No bias was noted in sex or age distribution between these two groups. No significant difference was noted not only in blood test items (WBC counts, Hb, Ht, platelet counts, or serum EPO), but also in the JAK2V617F . These three patients had different mutations 15) , all of which had been reported previously 19) .
Occurrence of thrombosis
A history of thrombosis was observed in twenty (20.2%) and fourteen patients (20.3%) in Group A and Group B, respectively. Thus, there was no significant difference in its frequency between the two groups. This frequency was almost consistent with the findings of previous foreign retrospective studies on PV patients (16-38%)
20)-23)
. The results of thrombosis based on the site of onset are shown in Table-3 . A previous study reported that arterial thrombosis was commonly observed in PV patients 21) . Arterial thrombosis (18 cases, 72%) was also more common than venous thrombosis (7 cases, 28%) in the present study. The incidence of cerebral infarction was the highest in patients with arterial thrombosis, stroke (14 Table-3 Thrombotic events cases, 56%), followed by myocardial infarction or angina, which required catheterization (3 cases, 12%), and then splenic infarction (1 case, 4%). The incidence of leg vein thrombosis was the highest in patients with venous thrombosis (5 cases, 20%), followed by pulmonary infarction (1 case, 4%), and then relatively rare hepatic vein thrombosis (1 case, 4%). No significant difference was observed in the frequency of arterial or venous thrombosis between Group A (n = 25, 72.0% vs. 28.0%) and Group B (n = 18, 61.1% vs. 38.9%)(p = 0.5205). When 99 PV patients diagnosed by the BCSH criteria were divided into two groups according to the occurrence of thrombosis, splenomegaly was strongly associated with thrombosis (Table-4) . No relationship was observed against the JAK2V617F allele burden, age, WBC, smoking, or hypertension as variables (Table-4) . A high WBC count (>15,000/μl) and JAK2V617F allele burden (≧50%), which have been identified as risk factors for thrombosis 24)-26) ,
were not significantly different in this analysis. Consistent with previous findings in which patients with MPN repeatedly developed thrombosis 23) , five out of 20 patients repeatedly developed thrombosis in the present study.
Discussion
We recently defined cases clinically suspected of having PV, with low Hb levels in spite of a high RBC count, as"suspected PV."The JAK2V617F allele burdens of these cases were almost the same as those of PV cases that met the WHO classification. Among 40 suspected PV patients, 11 were diagnosed with PV according to the BCSH criteria 15) . In the present study, we compared hematological and clinical aspects between patients who met the BCSH criteria (Group A) and those who met the WHO criteria (Group B), and found no significant differences in clinical backgrounds between Group A and Group B. In addition, the distribution of the JAK2V617F allele burden was not significantly different between these groups. Barbui et al. defined PV cases with Hb levels that were lower than the WHO criteria (males: < 18.5 g/dl; females: < 16.5 g/dl) and whose bone marrow biopsy met the pathological criteria as"masked PV" , thereby emphasizing the importance of bone marrow biopsy 17) . In our analysis, five of the 30 patients diagnosed with PV by the BCSH criteria only whose marrow biopsy findings corresponded to those of PV, but did not meet the WHO criteria for Hb, were diagnosed with masked PV (Table-2 , column c; n = 2, column d; n = 3). Thus, some patients with"masked PV"were diagnosed with PV using the BSCH diagnostic criteria of the BCSH criteria. Silver et al. previously characterized"masked PV"patients as follows; predominantly male, higher platelet counts, and more severe BM reticulin fibrosis 12) . Consistent with these findings, the ratio of males to females in our"masked PV"patients was 4 to 1, although the number of patients was very small (n = 5). However, no significant difference was observed in platelet counts between the five"masked PV"patients and defined PV patients diagnosed by the WHO criteria (mean ± SD × 10 4 /μl; 43.6 ± 9.9 vs 59.5 ± 4.4)(p = 0.1544).
Although the exon 12 gene mutation was detected at a low frequency (3 cases, 3%), as previously reported abroad 19) , some PV cases may be overlooked unless the exon 12 mutation is analyzed in JAK2V617F-negative cases; however, all three patients with the exon 12 mutation met the WHO criteria for Hb in the present study. The causal relationship between thrombosis and the JAK2V617F allele burden remains controversial. Vannucchi et al. reported that cardiovascular events may occur in patients with a > 75% JAK2V617F allele burden 27) . In the present study, three patients with cardiovascular diseases had a > 75% JAK2V617F allele burden. Cerebral infarction was the most common arterial thrombosis, while DVT was the most common venous thrombosis, which is consistent with previous findings 25) . The prevalence of risk factors for cardiovascular events (smoking, hypertension, dyslipidemia, and diabetes mellitus) was analyzed; however, these were not recognized as risk factors for thrombosis (data not 24) , this discrepancy may be explained by differences in populations between Japan and European countries. In consideration of the similar frequencies (20%) of thrombosis between Groups A and B, it may be beneficial to select patients suspected of having PV using the BCSH criteria for therapeutic interventions to prevent thrombosis.
A recent study demonstrated that PV and ET patients with a > 50% or increasing JAK2V617F allele burden were both more likely to develop myelofibrosis and thrombosis 26) . Thus, the allele burden should be measured over time, as well as at the initial diagnosis. In addition, according to the BCSH criteria, PV can only be diagnosed according to the JAK2V617F mutation and Ht level, and a pathological examination is not required. Thus, mimic ET accompanied by thrombocytosis and initial/pre-polycythemic PV may not be diagnosed by the BCSH criteria in patients with Ht levels that do not meet the diagnostic criteria 28) . However, in contrast to PV cases, most ET cases showed a < 50% JAK2V617F allele burden 29) . Furthermore, ET with a high allele burden is more likely to transit to PV 29) . Our method in which the allele burden was combined with the BCSH criteria may be useful; however, further studies are warranted.
In conclusion, PV cases diagnosed by the BCSH criteria showed the same clinical picture as those diagnosed by the WHO criteria. In view of actual clinical settings, the diagnostic criteria of the BCSH criteria may be useful for the diagnosis of PV in Japanese patients.
